Viridian Therapeutics (VRDN) Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. ANET
3. NKE
4. PANW
5. CL
6. SNDK
7. TAP
8. DELL
9. ROIV
10. BAC

Go back to Viridian Therapeutics (VRDN) Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
(NASDAQ: VRDN) Delayed: 22.92 -0.04 (0.17%)
Previous Close $22.96    52 Week High $ 
Open $22.62    52 Week Low $ 
Day High $23.03    P/E N/A 
Day Low $22.62    EPS $ 
Volume 759,916